Preface -- Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy? -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- The relationship between DNA-repair genes, cellular radiosensitivity and the response of tumors and normal tissues to radiotherapy -- Important Roles of ERCC1 in DNA Repair and Targeted Therapy -- The role of BRCA1 and BRCA2 in anticancer drug therapy -- DNA-PK in CLL Chemotherapy -- Poly(ADP) ribose polymerase at the interface of DNA damage signalling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a Therapeutic Target -- Telomeres, Telomerase and DNA Damage Response in Cancer Therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.

This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin.  The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1.  Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling  is examined.